Filed on behalf of: Pharmacyclics LLC

Entered on: March 6, 2025

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BeiGene USA, Inc. and BeiGene, LTD.,
Petitioner,

v.

Pharmacyclics LLC,
Patent Owner.

PGR2024-00009
Patent 11,672,803

PATENT OWNER'S UPDATED EXHIBIT LIST

Pursuant to the Board's July 11, 2024 Order (Paper 21), Patent Owner submits as an exhibit (Exhibit 2124) the decision rendered on Patent Owner's Certificate of Correction within ten business days of the March 4, 2025 decision date.

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner Pharmacyclics LLC respectfully submits the following current exhibit list:

Ex.	Description
2001	Douglas J. Marcotte et al., *Structures of Human Bruton's Tyrosine Kinase in Active and Inactive Conformations Suggest a Mechanism of Activation for TEC Family Kinases*, 19 Protein Science 429 (2010) ("Marcotte 2010")
2002	Michael Hallek et al., *Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Report from the International Workshop on Chronic Lymphocytic Leukemia Updating the National Cancer Institute–Working Group 1996 Guidelines*, 111 Blood 5446 (2008)
2003	Michael Hallek et al., *iwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL*, 131 Blood 2745 (2018)
2004	Press Release, AbbVie, *IMBRUVICA® (Ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent* (Oct. 28, 2015), https://www.prnewswire.com/news-releases/imbruvica-ibrutinib-awarded-prix-galien-2015-best-pharmaceutical-agent-300167630.html
2005	USPTO Non-Final Rejection issued in U.S. Patent Application No. 18/180,064 (Jan. 9, 2024)
2006	U.S. Patent No. 10,570,139
2007	U.S. Patent No. 11,142,528

Ex.	Description
2008	[Proposed] Request for Correction of Inventorship in Patent Under 37 C.F.R.§ 1.324 (Patent No. 11,672,803) (U.S.P.T.O. July 10, 2020)
2009	U.S. Patent & Trademark Office, Certificate of Correction of U.S. Patent No. 11,672,803 (U.S. Pat. Appl. No. 16/926,280), dated July 15, 2024
2010	Declaration of Michael J. Eck, M.D., Ph.D. ("Eck Decl.")
2011	*Curriculum Vitae* of Michael J. Eck, M.D., Ph.D.
2012	Declaration of David A. Scott, Ph.D. ("Scott Decl.")
2013	*Curriculum Vitae* of David A. Scott, Ph.D.
2014	Declaration of Stephen E. Spurgeon, M.D. ("Spurgeon Decl.")
2015	*Curriculum Vitae* of Stephen E. Spurgeon, M.D.
2016	Declaration of Ingrid Hsieh-Yee, Ph.D. ("Hsieh-Yee Decl.")
2017	*Curriculum Vitae* of Ingrid Hsieh-Yee, Ph.D.
2018	Deposition transcript of Hollis Showalter, Ph.D., *BeiGene USA, Inc. v. Pharmacyclics LLC*, No. PGR2024-00009 (P.T.A.B. July 18, 2024) ("Showalter Dep.")
2019	U.S. Patent No. 6,150,359 (Exhibit 1 to the Showalter Dep. (Ex. 2018))
2020	Yunhang Guo et al., *Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases*, 66 J. Med. Chemistry 4025 (2023) (Exhibit 2 to the Showalter Dep. (Ex. 2018))
2021	Deposition transcript of Steven Rosen, M.D., *BeiGene USA, Inc. v. Pharmacyclics LLC*, No. PGR2024-00009 (P.T.A.B. June 17, 2024) ("Rosen Dep.")
2022	Shuo Ma & Steven T. Rosen, *Signal Transduction Inhibitors in Chronic Lymphocytic Leukemia*, 23 Current Op. Oncology 601 (2011) (Exhibit 1 to the Rosen Dep. (Ex. 2021))

Ex.	Description
2023	U.S. Patent No. 7,435,820 B2
2024	U.S. Patent No. 10,358,446 B2
2025	U.S. Patent Application Publication No. 2008/0108636 A1
2026	U.S. Patent Application Publication No. 2010/0160303 A1
2027	International Patent Application Publication No. WO 2010/126960 A1
2028	Irini Akritopoulou-Zanze & Philip J. Hajduk, *Kinase-Targeted Libraries: The Design and Synthesis of Novel, Potent, and Selective Kinase Inhibitors*, 14 Drug Discovery Today 291 (2009)
2029	Misty M. Attwood et al., *Trends in Kinase Drug Discovery: Targets, Indications and Inhibitor Design*, 20 Nature Revs. Drug Discovery 839 (2021)
2030	Frances C. Bernstein et al., *The Protein Data Bank: A Computer-Based Archival File for Macromolecular Structures*, 80 Eur. J. Biochemistry 319 (1977)
2031	Caterina Bissantz et al., *A Medicinal Chemist's Guide to Molecular Interactions*, 53 J. Med. Chemistry Persp. 5061 (2010)
2032	RESERVED
2033	Philip Cohen, *Protein Kinases — The Major Drug Targets of the Twenty-First Century?*, 1 Nature Revs. Drug Discovery 309 (2002)
2034	Stephane De Cesco et al., *Covalent Inhibitors Design and Discovery*, 138 Eur. J. Med. Chemistry 96 (2017)
2035	Richard A. Friesner et al., *Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy*, 47 J. Med. Chemistry 1739 (2004)
2036	Richard A. Friesner et al., *Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein – Ligand Complexes*, 49 J. Med. Chemistry 6177 (2006)

Ex.	Description
2037	*Glide 5.5 User Manual*, Schrödinger, LLC (2009)
2038	Vijaya Gracias et al., *Scaffold Oriented Synthesis. Part 2: Design, Synthesis and Biological Evaluation of Pyrimido-Diazepines as Receptor Tyrosine Kinase Inhibitors*, 18 Bioorganic Med. Chemistry Letters 2691 (2008)
2039	Yunhang Guo et al., *Supporting Information* (pp. S1-S50) to *Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase*, 62 J. Med. Chemistry 7923 (2019) (Exhibit 1053)
2040	Doris Hafenbradl et al., *In Vitro Characterization of Small-Molecule Kinase Inhibitors*, ch. 1 (pp. 3–43) in PROTEIN KINASES AS DRUG TARGETS (Bert Klebl, Gerhard Müller & Michael Hamacher eds., 2011)
2041	Thomas A. Halgren et al., *Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening*, 47 J. Med. Chemistry 1750 (2004)
2042	Lee A. Honigberg et al., *Supporting Information* (pp. 1-2) to *The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and Is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy*, 107 Proc. Nat'l Acad. Scis. 13075 (2010) (Exhibit 1055)
2043	Louise N. Johnson, *Protein Kinase Inhibitors: Contributions from Structure to Clinical Compounds*, 42 Q. Revs. of Biophysics 1 (2009)
2044	RESERVED
2045	Hezekiel Mathambo Kumalo et al., *Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls*, 20 Molecules 1984 (2015)
2046	Betty Lam et al., *Discovery of TAK-659 an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)*, 26 Bioorganic Med. Chemistry Letters 5947 (2016)

Ex.	Description
2047	Roman A. Laskowski & Mark B. Swindells, *LigPlot+: Multiple Ligand — Protein Interaction Diagrams for Drug Discovery*, 51 J. Chem. Info. Modeling 2778 (2011)
2048	Laurent Le Corre et al., *Synthesis and Biological Evaluation of a Triazole-Based Library of Pyrido[2,3-d]pyrimidines as FGFR3 Tyrosine Kinase Inhibitors*, 8 Organic Biomolecular Chemistry 2164 (2010)
2049	Kui Lin et al., *An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt*, 5 Sci. Signaling 1 (2012)
2050	Qingjie Liu et al., *Design and Synthesis of Carbazole Carboxamides as Promising Inhibitors of Bruton's Tyrosine Kinase (BTK) and Janus Kinase 2 (JAK2)*, 25 Bioorganic Med. Chemistry Letters 4265 (2015)
2051	RESERVED
2052	Frank Lovering et al., *Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success*, 52 J. Med. Chemistry 6752 (2009)
2053	Moosa Mohammadi et al., *Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors*, 276 Sci. 955 (1997)
2054	Garrett M. Morris et al., *AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility*, 30 J. Computational Chemistry 2785 (2009)
2055	T. G. Murali Dhar et al., *Synthesis and SAR of p38α MAP Kinase Inhibitors Based on Heterobicyclic Scaffolds*, 17 Bioorganic Med. Chemistry Letters 5019 (2007)
2056	Albert C. Pierce et al., *Docking Study Yields Four Novel Inhibitors of the Protooncogene Pim-1 Kinase*, 51 J. Med. Chemistry 1972 (2008)
2057	Krishna P. Ravindranathan et al., *Discovery of Novel Fibroblast Growth Factor Receptor 1 Kinase Inhibitors by Structure-Based Virtual Screening*, 53 J. Med. Chemistry 1662 (2010)

Ex.	Description
2058	Robert Roskoski, Jr., *Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A 2021 Update*, 165 Pharmacological Rsch. 105463 (2021)
2059	Juswinder Singh et al., *The Resurgence of Covalent Drugs*, 10 Nature Revs. Drug Discovery 307 (2011)
2060	Michael J. Waring, *Lipophilicity in Drug Discovery*, 5 Expert Op. Drug Discovery 235 (2010)
2061	Scott H. Watterson et al., *Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4*H*)-yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-yl)-2,3,4,9-Tetrahydro-1*H*-Carbazole-8-Carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers*, 59 J. Med. Chemistry 9173 (2016)
2062	RESERVED
2063	Xuejun Zhang et al., *Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor*, 11 Am. Cancer Soc'y Med. Chemistry Letters 1863 (2020)
2064	RESERVED
2065	Xavier C. Badoux et al., *What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?*, 6 Current Hematologic Malignancy Reps. 36 (2011)
2066	Fleur Broekman et al., *Tyrosine Kinase Inhibitors: Multi-Targeted or Single-Targeted?*, 2 World J. Clinical Oncology 80 (2011)
2067	Brukinsa® (Zanubrutinib), Prescribing Information (revised June 2024)
2068	Andre T. Brunetto et al., *Early Oncology Clinical Trial Design in the Era of Molecular-Targeted Agents*, 6 Future Oncology 1339 (2010)
2069	Jeffrey Bryan & Gautam Borthakur, *Role of Rituximab in First-Line Treatment of Chronic Lymphocytic Leukemia*, 7 Therapeutics Clinical Risk Mgmt. 1 (2011)

Ex.	Description
2070	Bruce D. Cheson et al., *Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia*, 30 J Clinical Oncology 2820 (2012)
2071	RESERVED
2072	RESERVED
2073	Kirsten Fischer et al., *Long-Term Remissions After FCR Chemoimmunotherapy in Previously Untreated Patients with CLL: Updated Results of the CLL8 Trial*, 127 Blood 208 (2016)
2074	John G. Gribben, *How I Treat CLL Up Front*, 115 Blood 187 (2010)
2075	John G. Gribben, *Chronic Lymphocytic Leukemia: Planning for an Aging Population*, 1-15 (Author Manuscript) (2010) (*final form at* 10 Expert Revs. Anticancer Therapy 1389 (Sept. 2010))
2076	RESERVED
2077	Friedrich Grimminger et al., *Targeting Non-Malignant Disorders with Tyrosine Kinase Inhibitors*, 9 Nature 956 (2010)
2078	Sarah E. M. Herman et al., *Phosphatidylinositol 3-Kinase-δ Inhibitor CAL-101 Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia by Antagonizing Intrinsic and Extrinsic Cellular Survival Signals*, 116 Blood 2078 (2010)
2079	Imbruvica® (Ibrutinib), Prescribing Information (revised May 2024)
2080	Michael J. Keating et al., *Therapeutic Role of Alemtuzumab (Campath-1H) in Patients Who Have Failed Fludarabine: Results of a Large International Study*, 99 Blood 3554 (2002)
2081	Christophe Le Tourneau et al., *Dose Escalation Methods in Phase I Cancer Clinical Trials*, 101 J. Nat'l Cancer Inst. 708 (2009)
2082	Patricia M. LoRusso et al., *An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics*, 16 Clinical Cancer Rsch. 1710 (2010)

Ex.	Description
2083	Vicki A. Morrison, *Infectious Complications of Chronic Lymphocytic Leukaemia: Pathogenesis, Spectrum of Infection, Preventive Approaches*, 23 Best Prac. Rsch. Clinical Haematology 145 (2010)
2084	Jayant Narang et al., Meeting Abstract: *Bruton Tyrosine Kinase Inhibitors (BTKi) Therapies in Chronic Lymphocytic Leukemia (CLL): Review of Multiple Trials Data for Incidence of Lymphocytosis and Designation of Partial Response with Lymphocytosis (PRL)*, 39 J. Clinical Oncology (2021), https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.e19502
2085	C. Natoli et al., *Tyrosine Kinase Inhibitors*, 10 Current Cancer Drug Targets 462 (2010)
2086	Andrew D. Zelenetz et al., *Non-Hodgkin's Lymphomas: Clinical Practice Guidelines in Oncology*™, 8 J. Nat'l Comprehensive Cancer Network 288 (2010)
2087	Nat'l Comprehensive Cancer Network (NCCN), *NCCN Guidelines for Patients: Chronic Lymphocytic Leukemia 2024* (2024), https://www.nccn.org/patients/guidelines/content/PDF/cll-patient.pdf
2088	Nat'l Libr. of Med., Nat'l Ctr. for Biotechnology Info., *Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants with Relapsed/ Refractory NHL and CLL* (ClinicalTrials.gov ID No. NCT01659255), ClinicalTrials.gov (last updated Mar. 16, 2021), https://clinicaltrials.gov/study/NCT01659255?id=NCT01659255
2089	Nat'l Libr. Of Med., Nat'l Ctr. For Biotechnology Info., *A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants with Relapsed/Refractory Chronic Lymphocytic Leukemia (ALPINE)* (ClinicalTrials.gov ID No. NCT03734016), ClinicalTrials.gov (last updated Apr. 1, 2024), https://clinicaltrials.gov/study/NCT03734016?id=NCT03734016

Ex.	Description
2090	Nat'l Libr. of Med., Nat'l Ctr. for Biotechnology Info., *Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma* (ClinicalTrials.gov ID No. NCT03206918), ClinicalTrials.gov (last updated Oct. 4, 2021), https://clinicaltrials.gov/study/NCT03206918?id=NCT03206918
2091	Sabine Ponader et al., *The Bruton Tyrosine Kinase Inhibitor PCI-32765 Thwarts Chronic Lymphocytic Leukemia Cell Survival and Tissue Homing In Vitro and In Vivo*, 119 Blood 1182 (2012)
2092	Lisa A. Raedler, *Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia*, 8 Am. Health Drug Benefits 66 (2015)
2093	RESERVED
2094	Lukáš Smolej, *How I Treat Elderly or Comorbid Patients with Chronic Lymphocytic Leukemia*, 53 Acta Medica 213 (2010)
2095	Lynette A. Smyth & Ian Collins, *Measuring and Interpreting the Selectivity of Protein Kinase Inhibitors*, 2 J. Biological Chemistry 131 (2009)
2096	Stephan Stilgenbauer & Thorsten Zenz, *Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia*, 2010 Hematology 481 (2010)
2097	Tamar Tadmor et al., *Improved Survival of Patients with Chronic Lymphocytic Leukemia Between 1998–2022, Including the Era of Target Therapies with BCL2 and BTK Inhibitors*, 44 Anticancer Rsch. 2109 (2024)
2098	József Tímár & Balázs Döme, *Antiangiogenic Drugs and Tyrosine Kinases*, 8 Anti-Cancer Agents Med. Chemistry 462 (2008)
2099	Harriet S. Walter et al., *A Phase 1 Clinical Trial of the Selective BTK Inhibitor ONO/GS-4059 in Relapsed and Refractory Mature B-Cell Malignancies*, 127 Blood 411 (2016)

Ex.	Description
2100	Harriet S. Walter et al., *Long-Term Follow-Up of Patients with CLL Treated with the Selective Bruton's Tyrosine Kinase Inhibitor ONO/GS-4059*, 129 Blood 2808 (2017)
2101	Wei Xu et al., *Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with the BTK Inhibitor Zanubrutinib: Phase 2, Single-Arm, Multicenter Study*, 13 J. Hematology Oncology 1 (2020)
2102	Libr. of Cong., *Network Dev. & MARC Standards Off., pts. VII–X, Understanding MARC Bibliographic: Machine-Readable Cataloging*, http://www.loc.gov/marc/umb/um07to10.html (accessed Aug. 5, 2024, 3:40 PM)
2103	Douglas J. Marcotte et al., *Structures of Human Bruton's Tyrosine Kinase in Active and Inactive Conformations Suggest a Mechanism of Activation for TEC Family Kinases*, 19 Protein Science 429 (2010), https://onlinelibrary.wiley.com/doi/epdf/10.1002/pro.321 (copy from the Publisher)
2104	Douglas J. Marcotte et al., *Structures of Human Bruton's Tyrosine Kinase in Active and Inactive Conformations Suggest a Mechanism of Activation for TEC Family Kinases*, 19 Protein Science 429 (2010) (copy from the National Library of Medicine)
2105	Nat'l Libr. of Med., Protein Science, https://catalog.nlm.nih.gov/permalink/01NLM_INST/1o1phhn/alma997186893406676 (bibliography and Machine-Readable Cataloging (MARC) records)
2106	Nat'l Libr. of Med., LocatorPlus (May 12, 2009, archived by Internet Archive), https://web.archive.org/web/20090512190928/http://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local&PAGE=First (accessed June 23, 2024, 1:35 PM)
2107	Douglas J. Marcotte et al., *Structures of Human Bruton's Tyrosine Kinase in Active and Inactive Conformations Suggest a Mechanism of Activation for TEC Family Kinases*, 19 Protein Science 429 (2010) (PubMed record), https://pubmed.ncbi.nlm.nih.gov/20052711/ (accessed June 12, 2024, 2:43 PM)

Ex.	Description
2108	Nat'l Libr. of Med., PubMed (May 5, 2010, & May 6, 2010, archived by Internet Archive), at https://web.archive.org/web/20100505013751/ncbi.nlm.nih.gov/pubmed and https://web.archive.org/web/20100506160612/http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=helppubmed&part=pubmedhelp, respectively (accessed July 28, 2024, 8:49 PM & Aug. 3, 2024, 10:29 AM, respectively)
2109	References citing Douglas J. Marcotte et al., *Structures of Human Bruton's Tyrosine Kinase in Active and Inactive Conformations Suggest a Mechanism of Activation for TEC Family Kinases*, 19 Protein Science 429 (2010) (obtained from Google Scholar)
2110	Declaration of Nathaniel E Frank-White, Records Request Processor, Internet Archives (July 18, 2024)
2111	International Patent Application Publication No. WO 2008/121742 A2
2112	Declaration of Brenda L. Danek In Response to Petitioners' Objections to Admissibility of Evidence Submitted by Patent Owner [*served, not filed*]
2113	Maestro project archive file containing Glide docking results discussed in EX2010 ¶¶116-117 [*served, not filed*]
2114	Maestro project archive file containing Glide docking results discussed in EX2010 ¶¶184-185 [*served, not filed*]
2115	Pymol session file for figure at EX2010 ¶116 [*served, not filed*]
2116	Pymol session file for figure at EX2010 ¶117 [*served, not filed*]
2117	Pymol session file for figure at EX2010 ¶118 [*served, not filed*]
2118	Deposition transcript of Hollis Showalter, Ph.D., *BeiGene USA, Inc. v. Pharmacyclics LLC*, No. PGR2024-00009 (P.T.A.B. Nov. 8, 2024)
2119	Deposition transcript of James M. Veal, Ph.D., *BeiGene USA, Inc. v. Pharmacyclics LLC*, No. PGR2024-00009 (P.T.A.B. Nov. 22, 2024) ("Veal Dep.")

Ex.	Description
2120	James M. Veal, *Practical Use of Computational Chemistry in Kinase Drug Discovery*, ch. 16 (pp. 403-431) in KINASE INHIBITOR DRUGS (Rongshi Li & Jeffrey A. Stafford eds., 2009) (Exhibit 1 to the Veal Dep. (Ex. 2119))
2121	Jerry L. Adams, James Veal & Lisa Shewchuk, *Kinases*, ch. 2 (pp. 47-81) in PROTEIN CRYSTALLOGRAPHY IN DRUG DISCOVERY (R.E. Babine & S.S. Abdel-Meguid eds., 2004) (Exhibit 2 to the Veal Dep. (Ex. 2119))
2122	Errata for Deposition transcript of Michael J. Eck, M.D., Ph.D., *BeiGene USA, Inc. v. Pharmacyclics LLC*, No. PGR2024-00009 (P.T.A.B. Oct. 8, 2024) (Ex. 1110)
2123	Errata for Deposition transcript of David A. Scott, Ph.D., *BeiGene USA, Inc. v. Pharmacyclics LLC*, No. PGR2024-00009 (P.T.A.B. Sept. 27, 2024) (Ex. 1117)
2124	USPTO office communication: Supervisory Patent Examiner Response - Return for Certificate of Correction, Patent No. 11,672,803 (Mar. 4, 2025)

Respectfully submitted,

Dated: March 6, 2025

By: / David P. Frazier /

David P. Frazier (Reg. No. 47,576)
david.frazier@lw.com
Latham & Watkins LLP
555 Eleventh Street, NW, Ste. 1000
Washington, D.C. 20004-1304
Telephone: 202.637.2200
Fax: 202.637.2201

Counsel for Patent Owner
Pharmacyclics LLC

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 6th day of March, 2025, a true and correct copy of the foregoing **Patent Owner's Updated Exhibit List and Exhibit 2124** were served by electronic mail on Petitioner's lead and backup counsel at the following email addresses:

David I. Berl (Reg. No. 72,751)
Kevin Hoagland-Hanson (*pro hac vice*)
WILLIAMS & CONNOLLY LLP
680 Maine Ave SW
Washington, DC 20024
(202) 434-5000
dberl@wc.com
khoagland-hanson@wc.com

By: / David P. Frazier /

David P. Frazier (Reg. No. 47,576)
david.frazier@lw.com
Latham & Watkins LLP
555 Eleventh Street, NW, Ste. 1000
Washington, D.C. 20004-1304
Telephone: 202.637.2200
Fax: 202.637.2201

Counsel for Patent Owner
Pharmacyclics LLC